(Reuters) - The decision to push ahead with Phase III tests was reached taking into account the seriousness of the disease and a review of interim data from Phase II studies, Elan and Wyeth added.
"No conclusion about the Phase II study can be drawn until the study is completed and the final data are analyzed and released in 2008," they added.
Read more at Reuters.com Hot Stocks News
"No conclusion about the Phase II study can be drawn until the study is completed and the final data are analyzed and released in 2008," they added.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment